SMT202000557T1 - Derivati di benzoassazinone per il trattamento di malattie della pelle - Google Patents

Derivati di benzoassazinone per il trattamento di malattie della pelle

Info

Publication number
SMT202000557T1
SMT202000557T1 SM20200557T SMT202000557T SMT202000557T1 SM T202000557 T1 SMT202000557 T1 SM T202000557T1 SM 20200557 T SM20200557 T SM 20200557T SM T202000557 T SMT202000557 T SM T202000557T SM T202000557 T1 SMT202000557 T1 SM T202000557T1
Authority
SM
San Marino
Prior art keywords
treatment
skin diseases
benzoxazinone derivatives
benzoxazinone
derivatives
Prior art date
Application number
SM20200557T
Other languages
English (en)
Italian (it)
Inventor
Fredrik Wågberg
Göran Leonardsson
Original Assignee
Sixera Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sixera Pharma Ab filed Critical Sixera Pharma Ab
Publication of SMT202000557T1 publication Critical patent/SMT202000557T1/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/201,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SM20200557T 2014-01-23 2015-01-22 Derivati di benzoassazinone per il trattamento di malattie della pelle SMT202000557T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1430003 2014-01-23
PCT/SE2015/050062 WO2015112081A1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases
EP15740572.1A EP3097085B1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Publications (1)

Publication Number Publication Date
SMT202000557T1 true SMT202000557T1 (it) 2020-11-10

Family

ID=53681747

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200557T SMT202000557T1 (it) 2014-01-23 2015-01-22 Derivati di benzoassazinone per il trattamento di malattie della pelle

Country Status (18)

Country Link
US (2) US9695194B2 (enExample)
EP (1) EP3097085B1 (enExample)
JP (1) JP6448651B2 (enExample)
CN (1) CN106132941B (enExample)
AU (1) AU2015209761B2 (enExample)
CA (1) CA2934025C (enExample)
CY (1) CY1123477T1 (enExample)
DK (1) DK3097085T3 (enExample)
ES (1) ES2820868T3 (enExample)
HR (1) HRP20201500T1 (enExample)
HU (1) HUE051296T2 (enExample)
LT (1) LT3097085T (enExample)
PL (1) PL3097085T3 (enExample)
PT (1) PT3097085T (enExample)
RS (1) RS60830B1 (enExample)
SI (1) SI3097085T1 (enExample)
SM (1) SMT202000557T1 (enExample)
WO (1) WO2015112081A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112081A1 (en) * 2014-01-23 2015-07-30 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases
US10306885B2 (en) 2015-05-13 2019-06-04 Nihon Nohyaku Co., Ltd. Anthranilic acid ester compound or salt thereof, agricultural and horticultural microbicide comprising the compound, and method for using the microbicide
EP3402572B1 (en) * 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
KR20200021991A (ko) * 2017-06-16 2020-03-02 아지트라 인코포레이티드 Lekti 발현 재조합 미생물을 사용하는 네테르톤 증후군의 치료를 위한 조성물 및 방법
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US12360103B2 (en) 2018-04-20 2025-07-15 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
BR112022004972A2 (pt) 2019-09-18 2022-06-28 Genentech Inc Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
JP2022551583A (ja) * 2019-10-01 2022-12-12 モレキュラー スキン セラピューティクス,インコーポレイティド Klk5/7デュアル阻害剤としてのベンゾキサジノン化合物
GB202001447D0 (en) * 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
EP4346761A1 (en) 2021-06-01 2024-04-10 Sixera Pharma AB Oil-in-water emulsion of 6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,l-benzoxazin-4-one

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
GB1153994A (en) * 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
AU2826099A (en) 1998-03-24 1999-10-18 Novo Nordisk A/S Heterocyclic compounds regulating clotting
WO2004108139A2 (en) 2003-06-06 2004-12-16 Arexis Ab Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
TWI419884B (zh) 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物,其製備方法以及包含有此等衍生物的藥學組成物
WO2015112081A1 (en) * 2014-01-23 2015-07-30 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases

Also Published As

Publication number Publication date
HRP20201500T1 (hr) 2020-12-25
US9695194B2 (en) 2017-07-04
PL3097085T3 (pl) 2021-01-11
CA2934025A1 (en) 2015-07-30
CA2934025C (en) 2022-06-07
EP3097085A1 (en) 2016-11-30
US20170002021A1 (en) 2017-01-05
AU2015209761A1 (en) 2016-07-07
CN106132941B (zh) 2018-04-06
EP3097085A4 (en) 2017-08-09
JP2017503798A (ja) 2017-02-02
ES2820868T3 (es) 2021-04-22
EP3097085B1 (en) 2020-07-29
RS60830B1 (sr) 2020-10-30
CY1123477T1 (el) 2022-03-24
HUE051296T2 (hu) 2021-03-01
JP6448651B2 (ja) 2019-01-09
DK3097085T3 (da) 2020-10-26
US20170267692A1 (en) 2017-09-21
SI3097085T1 (sl) 2020-11-30
WO2015112081A1 (en) 2015-07-30
AU2015209761B2 (en) 2018-11-29
US10072024B2 (en) 2018-09-11
CN106132941A (zh) 2016-11-16
LT3097085T (lt) 2020-10-12
PT3097085T (pt) 2020-10-08

Similar Documents

Publication Publication Date Title
PT3212233T (pt) Terapia combinada para o tratamento de doenças
PT3097085T (pt) Derivados de benzoxazinona para tratamento de doenças de pele
IL253244B1 (en) Methods for treating retinal diseases
PL3122878T3 (pl) TERAPIA mRNA DO LECZENIA CHORÓB OCZU
PL3851537T3 (pl) Leczenie hiperbilirubinemii
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
SMT202100082T1 (it) Composti eteroarilici per il trattamento di malattie oftalmiche
IL246721B (en) History of 5-benzylisoquinoline for the treatment of cardiovascular diseases
PT3151814T (pt) Tratamento de uma lesão da pele
EP3340974A4 (en) METHODS OF TREATING DISEASES
GB201412578D0 (en) Treatment of neurological diseases
ZA201807692B (en) New use of product for skin treatment
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
EP3154637A4 (en) Treatment of virus-based diseases of the skin
IL259381B (en) Mirabegron for the treatment of retinal diseases
SI3302499T1 (sl) Zdravljenje mitohondrijskih bolezni
EP3271017A4 (en) Treatment of skin conditions
PT3851537T (pt) Tratamento da hiperbilirrubinemia
AU2015900943A0 (en) Treatment of skin conditions